Net clinical benefit analysis of Radiation Therapy Oncology Group 0525: A phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4076-4084

  Armstrong, Terri S ^a,b   Wefel, Jeffrey S ^b   Wang, Meihua ^c   Gilbert, Mark R ^b   Won, Minhee ^c   Bottomley, Andrew ^e   Mendoza, Tito R ^b   Coens, Corneel ^e   Werner Wasik, Maria ^d   Brachman, David G ^f   Choucair, Ali K ^g   Mehta, Minesh ^h  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Radiation Therapy Oncology Group Statistical Center   (United States)

^d THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^e EORTC DATA CENTER   (Belgium)

^f Arizona Oncology Services   (United States)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ADJUVANT THERAPY; ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CONFERENCE PAPER; CONSTIPATION; CONTROLLED ORAL WORD ASSOCIATION TEST; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DOSE DENSIFICATION; DROWSINESS; DYSPNEA; FEMALE; GLIOBLASTOMA; HAIR LOSS; HEADACHE; HOPKINS VERBAL LEARNING TEST; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NAUSEA; OVERALL SURVIVAL; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SEIZURE; TRAIL MAKING TEST; TUMOR DIAGNOSIS; VOMITING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; YOUNG ADULT;

EID: 84891791656     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.6067     Document Type: Conference Paper

References (21)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
2. Taphoorn MJ, Sizoo EM, Bottomley A: Review on quality of life issues in patients with primary brain tumors. Oncologist 15:618-626, 2010
3. Gilbert MR, Wang M, Aldape KD, et al: Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol 31:4085-4091, 2013
4. Efficace F, Bottomley A: Health related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer 38:1824-1831, 2002
5. Taphoorn MJ, Claassens L, Aaronson NK, et al: An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer 46:1033-1040, 2010
6. Scott NW, Fayers PM, Aaronson NK, et al: Reference Values Manual. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2008
7. Fayers PM, Aaronson NK, Bjordal K, et al: The EORTC QLQ-C30 Scoring Manual (3rd ed). Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001
8. Armstrong TS, Mendoza T, Gning I, et al: Validation of the MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol 80:27-35, 2006
9. Benedict RH, Schretten D, Groninger L, et al: Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12, 1998
10. Tombaugh TN: Trail Making Test A and B: Normative data stratified by age and education. Arch Clin Neuropsychol 19:203-214, 2004
11. Ruff RM, Light RH, Parker SB, et al: Benton Controlled Oral Word Association Test: Reliability and updated norms. Arch Clin Neuropsychol 11:329-338, 1996
12. Wefel JS, Saleeba AK, Buzdar AU, et al: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348-3356, 2010
13. Meyers CA, Smith JA, Bezjak A, et al: Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: Results of a randomized phase III trial. J Clin Oncol 22:157-165, 2004
14. Wefel JS, Cloughesy T, Zazzali JL, et al: Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660-668, 2011
15. Maringwa J, Quinten C, King M, et al: Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 22:2107-2112, 2011
16. Jacobson NS, Truax P: Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 59:12-19, 1991
17. Woodard JL, Benedict RH, Salthouse TA, et al: Normative data for equivalent, parallel forms of the Judgment of Line Orientation Test. J Clin Exp Neuropsychol 20:457-462, 1998
18. Levine AJ, Miller EN, Becker JT, et al: Normative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol 18:373-384, 2004
19. Shapiro AM, Benedict RH, Schretlen D, et al: Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol 13: 348-358, 1999
20. Quinten C, Maringwa J, Gotay CC, et al: Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851-1858, 2011
21. Gotay CC, Kawamoto CT, Bottomley A, et al: The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355-1363, 2008